MARKET COMPOSITE
MYOV - Myovant Sciences Ltd
Price
$0.00
+ 0.00 (0.00%)
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Stock Chart
leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra
leak data

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

leak data

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news
    11 High Growth UK Stocks to Buy03-01-2023 11:01:09 AM

    In this piece, we will take a look at 11 high growth U.K. stocks to buy. For more stocks, head on over to 5 High Growth U.K. Stocks to Buy. The United Kingdom, like the rest of the world, is facing the negative effects of the Russian invasion of Ukraine and rising inflation. The invasion […]

    Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

    Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022Net product revenue from U.S. sales of MYFEMBREE® of $10.5 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 49% and cumulative patients estima

    Seely steps into the top operational roles at a company where outgoing president and CEO Liz Homans guided two cancer cell therapies into the clinic.

    BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Comp

    BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant’s global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant’s Chief Executive Officer. Ms. Tomlin has over 25 years of human resources expe

    Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis, and a total company value of $2.9 billion

    The drug developer finally agreed to a takeover offer from its majority shareholder after rejecting advances earlier this month.

    10 Trending Stocks to Watch Today10-24-2022 20:54:24 PM

    In this article, we will take a look at the 10 trending stocks to watch today. If you want to see some more companies on the list, go directly to 5 Trending Stocks to Watch Today. U.S. stocks edged higher on Monday, with all three key indices in green as of 01:20 PM ET. On […]